Christopher R. Cline, CHIEF FINANCIAL OFFICER at Travere Therapeutics, Inc. (TVTX), sold 50,508 shares at $62.00 ($3.1M) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($3.1M) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.00 | 27,473 | $1.7M | 54.1% |
| 2 | $62.61 | 20,735 | $1.3M | 41.2% |
| 3 | $63.69 | 1,900 | $121K | 3.8% |
| 4 | $65.31 | 400 | $26K | 0.8% |
| Total | $62.34 avg | 50,508 | $3.1M | 100% |
| Filing → |
| TVTX | SELL | 2026-04-15 | $349K | — | Filing → |
| TVTX | SELL | 2026-02-05 | $56K | — | Filing → |
| TVTX | SELL | 2026-02-03 | $233K | — | Filing → |